% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • amiretiredyet1 amiretiredyet1 Oct 22, 2012 9:53 AM Flag

    Yoo Hoo Mr. Market

    SNTA’s only about to extend the life of 75% of second line adeno lung cancer patients from 7 to around 18 months! Annual sales projected to top $2 billion. (Slide 7 of Oct presentation.) That’s all.

    That’s all with 2nd line non-small cell lung cancer that is.

    Wait till they get to 1st line non-small lung cancer, breast, prostate, ovarian, head&neck, gastric & bladder cancer. Not to mention their monotherapy trials.

    I predict that this undiscovered diamond in the rough won’t stay the way for long.